Key Clinical Findings
Cabaletta Bio presented Phase 1/2 data for resecabtagene autoleucel (rese-cel) showing high rates of immunomodulator-free durability. In dermatomyositis patients, 100% (6 of 6) maintained moderate-to-major Total Improvement Score (TIS) responses through one year, with 83% achieving this by Week 16. For lupus nephritis, 100% (5 of 5) of patients with follow-up between six months and two years achieved DORIS remission and showed histologic response or remission via repeat kidney biopsies.
In systemic sclerosis, 71% (5 of 7) of patients achieved rCRISS-50 and 86% (6 of 7) achieved rCRISS-25 at one year. Additionally, five patients with interstitial lung disease showed a 9% mean improvement in forced vital capacity (FVC) at the one-year mark.
Technical Details and Safety Profile
Rese-cel is an investigational chimeric antigen receptor (CAR) T cell therapy administered as a single, weight-based intravenous infusion following preconditioning and the discontinuation of immunomodulators. Clinical experience across 71 patients spanning myositis, systemic sclerosis, lupus, and myasthenia gravis indicates a favorable benefit-risk profile:
- Cytokine Release Syndrome (CRS): 94% (67/71) experienced no or Grade 1 CRS; Grade 2 CRS occurred in 6% (4/71).
- Neurotoxicity: 96% (68/71) experienced no immune effector cell-associated neurotoxicity syndrome (ICANS).
- Other: No immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) was reported.
Background and Program Context
The data, with a cut-off date of September 4, 2026, are part of the REstoring SElf-Tolerance (RESET™) clinical development program. This program consists of single-arm, company-sponsored trials in dermatology, neurology, and rheumatology. The cohorts are designed to transition directly into registrational studies.
Significance and Outlook
The results suggest that a single dose of rese-cel can induce a durable immune reset, allowing patients to discontinue immunomodulators and reduce or eliminate steroid use. This is particularly significant for patients at risk of severe disability and end-organ damage who do not respond sufficiently to current therapies.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



